FOXO3 and urinary bladder carcinoma: Whereas, we demonstrated in a bladder cancer cell model, the TP agonist U46619 induced FOXO3 phosphorylation in a time dependent manner (Figure 2A) and was concurrent with increased activated ERK1/2.